Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study

Document Type : Research article

Authors

1 Department of Hematology and Oncology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Medical Oncology and Hematology, Iran University, Faculty of Medicine Tehran, Iran.

10.22037/ijpr.2021.115475.15409

Abstract

Relapsed/refractory acute myeloid leukemia (RR-AML) are important types of hematological malignancy for which no effective salvage chemotherapy has been approved. The main purpose of this study was to determine the effectiveness of adding Bortezomib to salvage chemotherapy protocol in RR-AML patients. In this prospective non-interventional study, 40 consecutive patients with RR-AML attending Taleghani Hospital who underwent salvage therapy, were enrolled and subdivided into salvage chemotherapy plus Bortezomib and salvage chemotherapy without Bortezomib and the therapeutic response, adverse effects, and survival among them were determined. The results in this study demonstrated that complete response was present in 30% and 25% in Bortezomib group and the other group, respectively and the partial response was seen in 35% and 50% and no response was present in 35% and 25%, respectively (P = 0.621). Furthermore, in each group, 15% had a side effect (P = 1.000). Mean survival was 8.2 and 7.1 in Bortezomib and the other group, respectively (P = 0.275). Based on the obtained results, it may be concluded that adding Bortezomib to salvage chemotherapy is feasible in RR-AML patients. For evaluation of efficacy further study is recommended.

Graphical Abstract

Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study

Keywords

References

References
(1) Sant M, Allemani C, Tereanu C, De Angelis R,
Capocaccia R, Visser O, Marcos-Gragera R,
Maynadié M, Simonetti A, Lutz JM and Berrino
F; HAEMACARE Working Group. Incidence
of hematologic malignancies in Europe by
morphologic subtype: results of the HAEMACARE
project. Blood (2010) 116: 3724-34.
(2) Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux
P, Grimwade D, Larson RA, Lo-Coco F, Naoe
T, Niederwieser D, Ossenkoppele GJ, Sanz
MA, Sierra J, Tallman MS, Löwenberg B and
Bloomfield. Diagnosis and management of acute
myeloid leukemia in adults: recommendations
from an international expert panel, on behalf of the
European LeukemiaNet. Blood (2010) 115: 453-
74.
(3) Sternberg DW, Aird W, Neuberg D, Thompson
L, MacNeill K, Amrein P and Shulman LN.
Treatment of patients with recurrent and primary
refractory acute myelogenous leukemia using
mitoxantrone and intermediate-dose cytarabine: a
pharmacologically based regimen. Cancer (2000)
88: 2037-41.
(4) Bringhen S, Larocca A, Rossi D, Cavalli M,
Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli
C, Levi A, Guglielmelli T, Benevolo G, Callea
V, Rizzo V, Cangialosi C, Musto P, De Rosa L,
Liberati AM, Grasso M, Falcone AP, Evangelista
A, Cavo M, Gaidano G, Boccadoro M and Palumbo
A. Efficacy and safety of once-weekly bortezomib
in multiple myeloma patients. Blood (2010) 116:
4745-53.
(5) Advani AS, Elson P, Matt E. Kalaycio ME,
Mukherjee S, Gerds AT, Hamilton BK, Hobson S,
Smith A, Rush ML, Bogati S, Biggins M, His ED,
Duong HK, Copelan EA, Reu FJ, Saunthararajah
Y, Nazha A, Makishima H, Przychodzen B, Dienes
B, Maciejewski JP, Carew JS, Carraway HE and
Sekeres MA. Bortezomib + MEC (Mitoxantrone,
Etoposide, Cytarabine) for Relapsed/ Refractory
Acute Myeloid Leukemia: Final Results of an
Expanded Phase 1 Trial. Blood (2014) 14: 978.
(6) Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu
S, Garzon R, Canning R, Geyer S, Wu YZ, Devine
SM, Klisovic R, Blum W, Marcucci G. Midostaurin,
bortezomib and MEC in relapsed/refractory acute
myeloid leukemia. Leuk Lymphoma (2016) 57:
2100-8.
(7) Udvardy M, Kiss A, Telek B, Szasz R, Batar
P, Remenyi G, Mehes E and Rejto L. 006
Bortezomib+chemotherapy based salvage
combinations in refractory AML, preliminary
results. Blood Rev. (2007) 26: 70024-3.
(8) Attar EC, De Angelo DJ, Sirulnik A, Wadleigh
M, Ballen KK, Miller KB, Galinsky I, Neuberg
D, Trehu E, Schenkein D, Stone RM and Amrein
PC. Addition of Bortezomib (Velcade) to AML
Induction Chemotherapy Is Well Tolerated and
Results in a High Complete Remission Rate. Blood
(2005) 106: 2782-82.
(9) Rashidi A, Linden MA, DeFor TE, Warlick E,
Bejanyan N, Yohe S, Weisdorf DJ and Ustun C.
History of consolidation is prognostic in acute
myeloid leukemia patients undergoing allogeneic
hematopoietic cell transplantation in minimal
residual disease-negative first complete remission.
Am. J. Hematol. (2017) 92: 1032-36
(10) Terwilliger T and Abdul-Hay M. Acute
lymphoblastic leukemia: a comprehensive review
and 2017 update. Blood Cancer J. (2017) 7: e577.
(11) De Kouchkovsky and Abdul-Hay M. ‘Acute
myeloid leukemia: a comprehensive review and
2016 update. Blood Cancer J. (2016) 7: e441
Iranian Journal of Pharmaceutical Research
Volume 20, Issue 4
Autumn 2021
Pages 29-32

Files

Share

How to cite

Statistics